ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
RE Miller, A Leary, CL Scott, V Serra, CJ Lord, D Bowtell, DK Chang, DW Garsed, J Jonkers, JA Ledermann, S Nik-Zainal, I Ray-Coquard, SP Shah, X Matias-Guiu, EM Swisher, LR Yates
Annals of Oncology | Oxford University Press (OUP) | Published : 2020
BACKGROUND: Homologous recombination repair deficiency (HRD) is a frequent feature of high-grade serous ovarian, fallopian tube and peritoneal carcinoma (HGSC) and is associated with sensitivity to PARP inhibitor (PARPi) therapy. HRD testing provides an opportunity to optimise PARPi use in HGSC but methodologies are diverse and clinical application remains controversial. MATERIALS AND METHODS: To define best practice for HRD testing in HGSC the ESMO Translational Research and Precision Medicine Working Group launched a collaborative project that incorporated a systematic review approach. The main aims were to (i) define the term 'HRD test'; (ii) provide an overview of the biological rational..View full abstract
This project was funded by the European Society for Medical Oncology (no grant number applies). There was no external funding of the event or manuscript production.